SOBI Swedish Orphan Biovitrum AB (publ)

STO · SE · Healthcare · Drug Manufacturers - Specialty & Generic · sobi.com

424.80SEK-0.70%Mkt Cap: 14.14B $P/E: 110.631d ago

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates…

Industry Peers

Drug Manufacturers - Specialty & Generic

Takeda Pharmaceutical Company Limited

$56.90BUSD

TEVA

Teva Pharmaceutical Industries Limited

United Therapeutics Corporation

Neurocrine Biosciences, Inc.

Elanco Animal Health Incorporated

$11.25BUSD

RDY

Dr. Reddy's Laboratories Limited

Amneal Pharmaceuticals, Inc.

$7.09BUSDP/E 41.5

HIMS

Hims & Hers Health, Inc.

$6.92BUSD

LNTH

Lantheus Holdings, Inc.

$6.54BUSDP/E 24.3

KNSA

Kiniksa Pharmaceuticals International, plc

Indivior Pharmaceuticals, Inc.

$4.25BUSDP/E 12.9

Key Statistics

Company

Market Cap14.14B USD

Enterprise Value15.79B USD

Revenue (TTM)2.93B USD

Gross Profit2.10B USD

Net Income (TTM)45.72M USD

Revenue/Share88.63 SEK

Last Price424.80 SEK

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees2.1K

CountrySE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

ISINSE0000872095

Valuation

P/E (Trailing)110.63

P/E (Forward)27.51

PEG0.25

EV/EBITDA13.30

EV/Revenue5.39

P/S4.86

P/B3.52

EPS (TTM)3.84

EPS (Forward)15.55

52W Range

266.0072% of range487.00

52W High487.00 SEK

52W Low266.00 SEK

Profitability

Gross Margin77.86%

Oper. Margin25.26%

EBITDA Margin40.54%

Profit Margin1.69%

ROE1.27%

ROA0.71%

Growth

Revenue Growth27.00%

Earnings Growth71.60%

Cash Flow & Leverage

Operating CF819.26M USD

CapEx (TTM)301.59M USD

FCF Margin11.15%

FCF Yield2.31%

Net Debt1.58B USD

Net Debt/EBITDA1.33

Balance Sheet

Debt/Equity0.30

Current Ratio0.88

Quick Ratio0.55

Book Value/Sh121.69 SEK

Cash/Share3.12 SEK

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 SEK

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.9 (Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)500.92 SEK

Upside (mean)+17.9%

Target Range350.00 SEK – 590.00 SEK

350.00+17.9% to mean590.00

# Analysts12

Ownership

Shares Out.348.00M

Float346.13M

Insiders9.80%

Institutions76.27%

Technical

SMA 50450.41 (-5.7%)

SMA 200417.36 (+1.8%)

Beta0.27

S&P 52W Chg14.58%

Avg Vol (30d)257.24K

Avg Vol (10d)262.33K

Technical Indicators

RSI (14)36.2

MACD-5.7536

MACD Signal-4.5068

MACD Hist.-1.2469

BB Upper454.63 SEK

BB Middle440.22 SEK

BB Lower425.81 SEK

BB Width6.55%

ATR (14)9.795 SEK

Vol Ratio (20d)0.70x